Mianhua Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mianhua Wu has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Wenting Li
First Clinical Medical College, Nanjing University of Chinese Medicine
4 shared publications- Jiege Huo
Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine
2 shared publications - Li Li
First Clinical Medical College, Nanjing University of Chinese Medicine, China
2 shared publications Liu Li
First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, 210023, China; Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine in Prevention and Treatment of Tumor, Nanjing, 210023, China
2 shared publicationsQingfeng Li
School of Acupuncture-Moxibustion and Tuina, School of Health Preservation and Rehabilitation, Nanjing University of Chinese Medicine, Nanjing, 210023, China
2 shared publicationsWenyue Zhao
Department of Oncology, Wuxi Hospital Affiliated to Nanjing University of Chinese Medicine, Wuxi, 214071, China
2 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1985999
Xiaoai Jiedu recipe promotes NLRP3 inflammasome activation by alleviating PINK1-mediated mitophagy in hepatocellular carcinoma
Background: The Xiaoai Jiedu recipe (XJR), a traditional Chinese medicinal formula, has been applied clinically for liver cancer management. XJR exhibits promising anti-tumor potential and may offer a novel strategy for oncological intervention. This study was designed to investigate the molecular mechanisms by which XJR exerts its pharmacological effects against hepatocellular carcinoma (HCC). Methods: In vivo assays were conducted employing an HCC xenograft mouse model, and HepG2 cells were employed in vitro . ELISA, immunohistochemistry (IHC), immunofluorescence (IF), RT-PCR and western blot were performed to detect PTEN-induced putative kinase 1 (PINK1)-mediated mitophagy and NLRP3 (NOD-like receptor protein 3) inflammasome activation. The cellular mitochondrial reactive oxygen species (ROS) levels were tested with DCFH-DA and MitoSOX. Transmission electron microscopy (TEM) and JC-1 were utilized to observe the mitochondrial morphology and function, as well as mitochondrial membrane potential (MMP) in the process of XJR intervention for HCC. Results: XJR prominently promoted pyroptosis by upregulating the related inflammatory cytokines levels in serum and HepG2 cells. The key targets include PINK1, parkin, p62, LC3B, TOMM20, COX IV, NLRP3, ASC, GSDMD, caspase1, IL-1β and IL-18 were observed. XJR disrupted PINK1-mediated mitophagy, which in turn increased mitochondrial ROS levels and promoted NLRP3 inflammasome assembly both in vitro and in vivo . Meanwhile, functional assays using pathway-specific inhibitors and siRNA-mediated knockdown further demonstrated that XJR suppresses mitophagy and enhances NLRP3 inflammasome activation via inhibition of the PINK1/parkin signaling pathway. Conclusions: The preliminary results of the present study suggested that XJR may alleviate PINK1-mediated mitophagy and motivate NLRP3 signaling pathway to subsequently exert anti-tumor effects in HCC.
- 27 October 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1985999
Open AccessXiaoai Jiedu recipe promotes NLRP3 inflammasome activation by alleviating PINK1-mediated mitophagy in hepatocellular carcinoma
Background: The Xiaoai Jiedu recipe (XJR), a traditional Chinese medicinal formula, has been applied clinically for liver cancer management. XJR exhibits promising anti-tumor potential and may offer a novel strategy for oncological intervention. This study was designed to investigate the molecular mechanisms by which XJR exerts its pharmacological effects against hepatocellular carcinoma (HCC). Methods: In vivo assays were conducted employing an HCC xenograft mouse model, and HepG2 cells were employed in vitro . ELISA, immunohistochemistry (IHC), immunofluorescence (IF), RT-PCR and western blot were performed to detect PTEN-induced putative kinase 1 (PINK1)-mediated mitophagy and NLRP3 (NOD-like receptor protein 3) inflammasome activation. The cellular mitochondrial reactive oxygen species (ROS) levels were tested with DCFH-DA and MitoSOX. Transmission electron microscopy (TEM) and JC-1 were utilized to observe the mitochondrial morphology and function, as well as mitochondrial membrane potential (MMP) in the process of XJR intervention for HCC. Results: XJR prominently promoted pyroptosis by upregulating the related inflammatory cytokines levels in serum and HepG2 cells. The key targets include PINK1, parkin, p62, LC3B, TOMM20, COX IV, NLRP3, ASC, GSDMD, caspase1, IL-1β and IL-18 were observed. XJR disrupted PINK1-mediated mitophagy, which in turn increased mitochondrial ROS levels and promoted NLRP3 inflammasome assembly both in vitro and in vivo . Meanwhile, functional assays using pathway-specific inhibitors and siRNA-mediated knockdown further demonstrated that XJR suppresses mitophagy and enhances NLRP3 inflammasome activation via inhibition of the PINK1/parkin signaling pathway. Conclusions: The preliminary results of the present study suggested that XJR may alleviate PINK1-mediated mitophagy and motivate NLRP3 signaling pathway to subsequently exert anti-tumor effects in HCC.
- Open Access
- 16 September 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1890536
Transcriptomic profiling identifies NLRP3-associated inflammatory signatures in acute radiation enteritis and characterizes the protective effects of Qing Hua Yi Chang formula
Background: Acute radiation enteritis (ARE) is a common complication of abdominal or pelvic radiotherapy characterized by inflammatory activation and epithelial barrier dysfunction. However, the molecular mechanisms underlying ARE remain incompletely understood. This study investigated transcriptomic alterations associated with ARE and evaluated the protective effects of Qing Hua Yi Chang Formula (QHYCF). Methods: A murine model of ARE was established using abdominal irradiation followed by QHYCF treatment. Histopathological analysis, TUNEL staining, RT-qPCR, western blotting, and ELISA were performed to assess intestinal injury and inflammatory responses. Transcriptomic profiling combined with bioinformatic analyses was used to identify inflammatory signatures and pathways associated with ARE. Results: QHYCF attenuated radiation-induced intestinal injury, particularly at the medium dose. Transcriptomic analysis revealed dysregulation of immune- and inflammation-related pathways after irradiation and identified NLRP3-associated inflammatory signaling as a prominent inflammatory alteration in ARE. QHYCF treatment was associated with reduced NLRP3 expression and decreased serum levels of IFN-γ, IL-1β, and IL-18. In addition, QHYCF partially restored Claudin-1 expression, suggesting improvement in epithelial barrier integrity. Conclusion: ARE progression is closely associated with inflammatory activation and epithelial barrier disruption. NLRP3-associated inflammatory alterations and Claudin-1 changes may represent molecular features associated with radiation-induced intestinal injury. QHYCF was associated with attenuation of inflammatory responses and preservation of epithelial barrier integrity.
- 16 September 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1890536
Open AccessTranscriptomic profiling identifies NLRP3-associated inflammatory signatures in acute radiation enteritis and characterizes the protective effects of Qing Hua Yi Chang formula
Background: Acute radiation enteritis (ARE) is a common complication of abdominal or pelvic radiotherapy characterized by inflammatory activation and epithelial barrier dysfunction. However, the molecular mechanisms underlying ARE remain incompletely understood. This study investigated transcriptomic alterations associated with ARE and evaluated the protective effects of Qing Hua Yi Chang Formula (QHYCF). Methods: A murine model of ARE was established using abdominal irradiation followed by QHYCF treatment. Histopathological analysis, TUNEL staining, RT-qPCR, western blotting, and ELISA were performed to assess intestinal injury and inflammatory responses. Transcriptomic profiling combined with bioinformatic analyses was used to identify inflammatory signatures and pathways associated with ARE. Results: QHYCF attenuated radiation-induced intestinal injury, particularly at the medium dose. Transcriptomic analysis revealed dysregulation of immune- and inflammation-related pathways after irradiation and identified NLRP3-associated inflammatory signaling as a prominent inflammatory alteration in ARE. QHYCF treatment was associated with reduced NLRP3 expression and decreased serum levels of IFN-γ, IL-1β, and IL-18. In addition, QHYCF partially restored Claudin-1 expression, suggesting improvement in epithelial barrier integrity. Conclusion: ARE progression is closely associated with inflammatory activation and epithelial barrier disruption. NLRP3-associated inflammatory alterations and Claudin-1 changes may represent molecular features associated with radiation-induced intestinal injury. QHYCF was associated with attenuation of inflammatory responses and preservation of epithelial barrier integrity.
- Open Access
- 14 September 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1937723
Pre-radiotherapy cachexia is associated with treatment discontinuation in patients with head and neck squamous cell carcinoma receiving definitive radiotherapy
Purpose: This study aimed to evaluate the association between pre-radiotherapy cachexia and treatment discontinuation, as well as other treatment-related outcomes, in patients with head and neck squamous cell carcinoma (HNSCC) receiving definitive radiotherapy. Methods: This single-center retrospective cohort study consecutively enrolled M0 HNSCC patients who received definitive radiotherapy between July 2023 and December 2025. Cachexia was defined using an operational approach based on core diagnostic variables available in the medical records, informed by the Asian Working Group for Cachexia (AWGC) 2023 criteria. The primary outcome was treatment discontinuation. Secondary outcomes included unplanned radiotherapy interruptions, treatment-related adverse events, timing of acute radiation toxicity, timing of acute myelosuppression, nutritional risk during radiotherapy, and blood transfusion requirements. Logistic regression analyses were performed to assess the association between cachexia and treatment discontinuation. Results: A total of 137 patients were included, of whom 72 (52.6%) were classified as having cachexia. Treatment discontinuation was significantly higher in the cachexia group compared to the non-cachexia group (25.0% vs. 4.6%; P<0.001), and the incidence of treatment-related adverse events was also higher (97.2% vs. 78.5%; P<0.001). The distribution of first documented acute radiation toxicity across fraction-based categories differed between groups (P = 0.037). No significant differences were observed in unplanned interruptions, timing of acute myelosuppression, nutritional risk, or transfusion requirements. In univariable logistic regression, cachexia was significantly associated with treatment discontinuation (OR = 6.89; 95% CI 1.92–24.67; P = 0.003). After adjustment for age, Eastern Cooperative Oncology Group (ECOG) performance status, and concurrent chemotherapy, cachexia remained significantly associated with treatment discontinuation (OR = 6.05; 95% CI, 1.63–22.49; P = 0.007). Sensitivity analysis using Firth’s penalized logistic regression yielded consistent results. Conclusions: In M0 HNSCC patients receiving definitive radiotherapy, pre-radiotherapy cachexia is significantly associated with treatment discontinuation and is accompanied by a higher incidence of treatment-related adverse events. Assessment of cachexia prior to radiotherapy may provide clinically relevant information on treatment tolerance and help identify patients at high risk of therapy discontinuation.
- 14 September 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1937723
Open AccessPre-radiotherapy cachexia is associated with treatment discontinuation in patients with head and neck squamous cell carcinoma receiving definitive radiotherapy
Purpose: This study aimed to evaluate the association between pre-radiotherapy cachexia and treatment discontinuation, as well as other treatment-related outcomes, in patients with head and neck squamous cell carcinoma (HNSCC) receiving definitive radiotherapy. Methods: This single-center retrospective cohort study consecutively enrolled M0 HNSCC patients who received definitive radiotherapy between July 2023 and December 2025. Cachexia was defined using an operational approach based on core diagnostic variables available in the medical records, informed by the Asian Working Group for Cachexia (AWGC) 2023 criteria. The primary outcome was treatment discontinuation. Secondary outcomes included unplanned radiotherapy interruptions, treatment-related adverse events, timing of acute radiation toxicity, timing of acute myelosuppression, nutritional risk during radiotherapy, and blood transfusion requirements. Logistic regression analyses were performed to assess the association between cachexia and treatment discontinuation. Results: A total of 137 patients were included, of whom 72 (52.6%) were classified as having cachexia. Treatment discontinuation was significantly higher in the cachexia group compared to the non-cachexia group (25.0% vs. 4.6%; P<0.001), and the incidence of treatment-related adverse events was also higher (97.2% vs. 78.5%; P<0.001). The distribution of first documented acute radiation toxicity across fraction-based categories differed between groups (P = 0.037). No significant differences were observed in unplanned interruptions, timing of acute myelosuppression, nutritional risk, or transfusion requirements. In univariable logistic regression, cachexia was significantly associated with treatment discontinuation (OR = 6.89; 95% CI 1.92–24.67; P = 0.003). After adjustment for age, Eastern Cooperative Oncology Group (ECOG) performance status, and concurrent chemotherapy, cachexia remained significantly associated with treatment discontinuation (OR = 6.05; 95% CI, 1.63–22.49; P = 0.007). Sensitivity analysis using Firth’s penalized logistic regression yielded consistent results. Conclusions: In M0 HNSCC patients receiving definitive radiotherapy, pre-radiotherapy cachexia is significantly associated with treatment discontinuation and is accompanied by a higher incidence of treatment-related adverse events. Assessment of cachexia prior to radiotherapy may provide clinically relevant information on treatment tolerance and help identify patients at high risk of therapy discontinuation.
- Open Access
- 5 August 2026
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 24 (1)
From multifaceted mechanisms to targeted strategies: advances in PANoptosomes as regulatory hubs of PANoptosis in cancer
- 5 August 2026
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 24 (1)
Open AccessFrom multifaceted mechanisms to targeted strategies: advances in PANoptosomes as regulatory hubs of PANoptosis in cancer
- Open Access
- 1 January 2025
- Published by Wiley in Human Mutation
- Vol. 2025 (1) , 6663166
AIF1L as a Ferroptosis‐Linked Biomarker in Microsatellite States–Driven Colorectal Cancer: Functional and Diagnostic Insights From Multiomics Analysis
Background: Microsatellite instability (MSI) serves as a crucial biomarker for immune checkpoint blockade therapy in colorectal cancer (CRC). However, only around 40% of MSI CRC patients benefit from ICB. Investigating the mechanisms underlying MSI CRC, particularly its association with cell death and the immune microenvironment, can provide insights to improve immunotherapy efficacy.Methods: Transcriptomic and clinical data of MSI CRC patients were collected from TCGA and GEO databases. Differential expression analysis, weighted gene coexpression network analysis, and Cox regression models were employed to identify five cell death–related prognostic genes (POU4F1, AIF1L, SLC18A1, INSL4, and HOXC6). Single‐cell analysis, immune infiltration analysis, and in vitro and in vivo experiments were conducted to validate their roles in MSI CRC.Results: The five‐gene risk model effectively stratified high‐ and low‐risk groups and predicted survival differences (AUC > 0.6). AIF1L exhibited elevated expression in MSI‐H groups and demonstrated a significant correlation with ferroptosis and immune cell infiltration. In vitro experiments showed that AIF1L boosted cell proliferation and migration via modulating ferroptosis, showing correspondence with in vivo experiments. Moreover, enrichment analysis revealed that AIF1L participated in immune‐related signaling pathways, potentially impacting the tumor microenvironment and patient prognosis.Conclusion: AIF1L may regulate MSI CRC progression by promoting ferroptosis, serving as a prospective biomarker for prognosis and a therapeutic target for personalized therapy. This study uncovers new mechanisms in MSI CRC and provides a foundation for optimizing immunotherapy, though further investigation into its specific roles is needed.
- 1 January 2025
- Published by Wiley in Human Mutation
- Vol. 2025 (1) , 6663166
Open AccessAIF1L as a Ferroptosis‐Linked Biomarker in Microsatellite States–Driven Colorectal Cancer: Functional and Diagnostic Insights From Multiomics Analysis
Background: Microsatellite instability (MSI) serves as a crucial biomarker for immune checkpoint blockade therapy in colorectal cancer (CRC). However, only around 40% of MSI CRC patients benefit from ICB. Investigating the mechanisms underlying MSI CRC, particularly its association with cell death and the immune microenvironment, can provide insights to improve immunotherapy efficacy.Methods: Transcriptomic and clinical data of MSI CRC patients were collected from TCGA and GEO databases. Differential expression analysis, weighted gene coexpression network analysis, and Cox regression models were employed to identify five cell death–related prognostic genes (POU4F1, AIF1L, SLC18A1, INSL4, and HOXC6). Single‐cell analysis, immune infiltration analysis, and in vitro and in vivo experiments were conducted to validate their roles in MSI CRC.Results: The five‐gene risk model effectively stratified high‐ and low‐risk groups and predicted survival differences (AUC > 0.6). AIF1L exhibited elevated expression in MSI‐H groups and demonstrated a significant correlation with ferroptosis and immune cell infiltration. In vitro experiments showed that AIF1L boosted cell proliferation and migration via modulating ferroptosis, showing correspondence with in vivo experiments. Moreover, enrichment analysis revealed that AIF1L participated in immune‐related signaling pathways, potentially impacting the tumor microenvironment and patient prognosis.Conclusion: AIF1L may regulate MSI CRC progression by promoting ferroptosis, serving as a prospective biomarker for prognosis and a therapeutic target for personalized therapy. This study uncovers new mechanisms in MSI CRC and provides a foundation for optimizing immunotherapy, though further investigation into its specific roles is needed.
- Open Access
- 23 November 2024
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 339, 119135
Xiaoai Jiedu recipe reduces cell survival and induces apoptosis in hepatocellular carcinoma by stimulating autophagy via the AKT/mTOR pathway
- 23 November 2024
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 339, 119135
Open AccessXiaoai Jiedu recipe reduces cell survival and induces apoptosis in hepatocellular carcinoma by stimulating autophagy via the AKT/mTOR pathway